• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.08% Nasdaq Down0.69%

    Anthera Pharmaceuticals, Inc. (ANTH)

    5.78 Down 0.42(6.77%) 4:00PM EDT
    |After Hours : 5.79 Up 0.01 (0.17%) 6:36PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Anthera Pharmaceuticals, Inc.
    25801 Industrial Boulevard
    Suite B
    Hayward, CA 94545
    United States - Map
    Phone: 510-856-5600
    Fax: 510-856-5597
    Website: http://www.anthera.com

    Index Membership:N/A
    Full Time Employees:20

    Business Summary 

    Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others. The company is also developing a Phase III product candidate Liprotamase, a non-porcine investigational pancreatic enzyme replacement therapy intended for the treatment of patients with exocrine pancreatic insufficiency. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Anthera Pharmaceuticals, Inc.

    Corporate Governance 
    Anthera Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 10. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Paul F. Truex MBA, 46
    Chief Exec. Officer, Pres and Director
    Ms. May Liu , 39
    Principal Accounting Officer, Compliance Officer and Sr. VP of Fin. & Admin.
    Dr. Debra Odink Ph.D., 51
    Chief Technology Officer and Sr. VP
    Dr. Colin Hislop M.D., 57
    Chief Medical Officer and Sr. VP
    Ms. Klara A. Dickinson-Eason , 47
    Chief Regulatory Officer and Sr. VP
    Dr. Paul Adams Ph.D., 52
    Sr. VP of Global Regulatory Affairs and Compliance
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders